Delcath Systems (NASDAQ:DCTH) Receiving Somewhat Positive Media Coverage, Analysis Finds – The Ledger Gazette

This post was originally published on this site

Headlines about Delcath Systems (NASDAQ:DCTH) have been trending somewhat positive recently, according to Accern. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Delcath Systems earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 45.6861858982675 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the media headlines that may have effected Accern Sentiment’s rankings:

Delcath Systems (DCTH) opened at 0.0999 on Friday. The stock’s market cap is $42.40 million. The firm has a 50 day moving average of $0.11 and a 200-day moving average of $0.10. Delcath Systems has a 12-month low of $0.02 and a 12-month high of $4.31.

ILLEGAL ACTIVITY NOTICE: “Delcath Systems (NASDAQ:DCTH) Receiving Somewhat Positive Media Coverage, Analysis Finds” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://ledgergazette.com/2017/09/15/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-delcath-systems-dcth-stock-price.html.

Delcath Systems Company Profile

Delcath Systems, Inc is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS).

Insider Buying and Selling by Quarter for Delcath Systems (NASDAQ:DCTH)

Receive News & Ratings for Delcath Systems Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Delcath Systems Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

This post was originally published on *this site*